These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38175554)

  • 1. [A scientifically grounded pharmacological treatment of ADHD].
    Vertessen K
    Ned Tijdschr Geneeskd; 2023 Dec; 168():. PubMed ID: 38175554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study.
    Matthijssen AM; Dietrich A; Bierens M; Kleine Deters R; van de Loo-Neus GHH; van den Hoofdakker BJ; Buitelaar JK; Hoekstra PJ
    Am J Psychiatry; 2019 Sep; 176(9):754-762. PubMed ID: 31109200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
    Inglis SK; Carucci S; Garas P; Häge A; Banaschewski T; Buitelaar JK; Dittmann RW; Falissard B; Hollis C; Kovshoff H; Liddle E; McCarthy S; Nagy P; Neubert A; Rosenthal E; Sonuga-Barke E; Wong I; Zuddas A; Coghill DC;
    BMJ Open; 2016 Apr; 6(4):e010433. PubMed ID: 27118284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of children and adolescents with ADHD with or without methylphenidate prescription at their first diagnostic assessment.
    De Rossi P; Pretelli I; Menghini D; D'Aiello B; Di Vara S; Vicari S
    Eur Arch Psychiatry Clin Neurosci; 2022 Dec; 272(8):1437-1442. PubMed ID: 35211779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
    Ng QX
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):112-116. PubMed ID: 27813651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
    van den Ban E; Souverein PC; Swaab H; van Engeland H; Egberts TC; Heerdink ER
    Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials.
    Castells X; Cunill R; Capellà D
    Eur J Clin Pharmacol; 2013 Mar; 69(3):347-56. PubMed ID: 22983311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients.
    Riera M; Castells X; Tobias A; Cunill R; Blanco L; Capellà D
    Psychopharmacology (Berl); 2017 Sep; 234(17):2657-2671. PubMed ID: 28631099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.